Merck KGaA Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Merck KGaA Insights data

Headline Published Journalists
Showing 3 of 60+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 22 Jul 2022 Lorem
Neglected Tropical Diseases: Non-Profits Lead the Way as Private Sectors Lags 30 Jun 2022 Adam Zamecnik
LoA Update: Merck KGaA’s Berzosertib Advancement Prospects Dip in Small-Cell Lung Cancer, Solid Tumors After Phase II Discontinuation 10 Jun 2022 Urte Fultinaviciute
LoA Update: Merck’s schistosomiasis asset levo-praziquantel sees its Likelihood of Approval rise after positive Phase III results 26 Nov 2021 Adam Zamecnik


Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.


Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships


Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.


Access more premium companies when you subscribe to Explorer